$57.71
-0.99-1.69%
After Hours: 4:02 PM EDT
Comments
Loading...
Latest Biomarin Pharmaceutical Stock News | NASDAQ:BMRN | Benzinga
Get the latest news on Biomarin Pharmaceutical stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Biomarin Pharmaceutical performance
Categories: All
Monday, May 12, 2025
Monday, May 05, 2025
Friday, May 02, 2025
Thursday, May 01, 2025
Wednesday, April 16, 2025
Wednesday, April 02, 2025
Thursday, March 20, 2025
Monday, February 24, 2025
Thursday, February 20, 2025
- Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews
- Scotiabank Maintains Sector Perform on Biomar...
- Citigroup Maintains Neutral on Biomarin Pharm...
- RBC Capital Reiterates Sector Perform on Biom...
- Cantor Fitzgerald Reiterates Overweight on Bi...
- Why Is BioMarin Stock Trading Higher On Thursday?
- Piper Sandler Maintains Overweight on Biomari...
- B of A Securities Maintains Buy on Biomarin P...
- BioMarin Pharma shares are trading higher aft...
Wednesday, February 19, 2025
Thursday, February 13, 2025
Wednesday, February 12, 2025
Sunday, January 19, 2025
Monday, January 13, 2025
Wednesday, January 08, 2025
Thursday, December 12, 2024
Monday, November 18, 2024
Friday, November 15, 2024
Wednesday, November 06, 2024
Tuesday, November 05, 2024
Wednesday, October 30, 2024
- BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
- Citigroup Maintains Neutral on Biomarin Pharm...
- Canaccord Genuity Maintains Hold on Biomarin ...
- Cantor Fitzgerald Maintains Overweight on Bio...
- JP Morgan Maintains Overweight on Biomarin Ph...
- RBC Capital Reiterates Sector Perform on Biom...
- Evercore ISI Group Maintains Outperform on Bi...
- In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical
- UBS Maintains Buy on Biomarin Pharmaceutical,...
- Baird Maintains Neutral on Biomarin Pharmaceu...
- William Blair Downgrades Biomarin Pharmaceuti...
